Related Experiment Video
Updated: Mar 21, 2026
06:18
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
Published on: August 18, 2023
3.9K
Engineering programmable CAR and antigen pairing via drug-gated light activation
Ziliang Huang1,2,3, Praopim Limsakul2,4, Yiqian Wu2,5
1Alfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA, USA.
Nature Communications
|March 20, 2026
Summary
This study introduces a new CAR T-cell therapy (DGLA-sPAT) that uses light and drugs to target solid tumors. This approach overcomes antigen escape and heterogeneity, improving safety and efficacy in cancer treatment.
Area of Science:
- Immunotherapy
- Oncology
- Biotechnology
Background:
- Chimeric antigen receptor (CAR) T-cell immunotherapy shows promise but faces challenges in solid tumors, including antigen escape and tumor heterogeneity.
- Current CAR T-cell therapies struggle with specificity and off-tumor toxicity, limiting their application in treating solid malignancies.
Purpose of the Study:
- To engineer a novel programmable CAR T-cell system (DGLA-sPAT) to overcome limitations of current CAR T-cell therapies in solid tumors.
- To enhance spatial control and safety of CAR T-cell activity using a drug-gated light-activation approach (DGLA) and synNotch-mediated programmable antigen-targeting CAR (sPAT).
Main Methods:
- Development of a high-affinity R-phycoerythrin (PE)-binding monobody for PE-programmable CAR construction.
- Implementation of a drug-gated light-activation approach (DGLA) to spatially confine CAR T-cell function.
- Integration of DGLA with synNotch-mediated programmable antigen-targeting CAR (sPAT) to create the DGLA-sPAT system for programmable CAR-antigen pairing.
Main Results:
- The DGLA-sPAT system successfully induced clinically validated antigens on tumor cells, acting as 'training centers' to recruit and activate CAR T cells.
- Demonstrated potent tumor suppression in vivo with localized T-cell activation and minimal off-tumor toxicity.
- The system enabled elimination of entire tumor populations by targeting broadly expressed tumor antigens.
Conclusions:
- The DGLA-sPAT system offers a modular and spatially controlled framework for CAR T-cell therapy in solid tumors.
- This approach effectively addresses challenges of antigen escape and tumor heterogeneity while significantly improving safety profiles.
- DGLA-sPAT represents a promising advancement for enhancing the efficacy and safety of CAR T-cell immunotherapy against solid tumors.
